Neil B. Sweig at Brenner Securities said Bristol-Myers's pharmaceutical sales increased 17 percent, led by a 20 percent jump in cardiovascular drugs.

"All three worked well together and were strong candidates to become chief executive," said Neil B. Sweig, a managing director at Brenner Securities.

Neil B. Sweig, a managing director with Brenner Securities, said Bristol-Myers Squibb's sales of infant formula were $550 million in this country last year.

"There is nothing automatic here," said Neil B. Sweig, an analyst at Brenner Securities.

Her father is the president of Brenner Securities, a brokerage in New York.

Neil B. Sweig, an analyst with Brenner Securities, reacted favorably to the company's report, saying, "They are operating on all eight cylinders in many dynamic markets."

"He has truly lit a fire under the F.D.A.," said Neil B. Sweig, a drug analyst with Brenner Securities.

But Neil B. Sweig of Brenner Securities said the drug would face "significant competition" when it lost its patent protection in January 1993.

Brenner Securities is currently in the retail and institutional brokerage business.

"The companies are forever tied to this business," said Neil Sweig at Brenner Securities.